# Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

> **NCT04305145** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Melanoma Stage III
- Melanoma Stage IV
- Skin Cancer Stage III
- Skin Cancer Stage IV
- Drug-Induced Colitis
- Drug Toxicity
- Immune-related Adverse Event

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Methylprednisolone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04305145
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-31
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305145, "Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04305145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*